Menopause medical therapy

Revision as of 05:55, 18 February 2021 by Rahmah Al-Edresi (talk | contribs)
Jump to navigation Jump to search

Menopause Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasonography

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Menopause medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Menopause medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Menopause medical therapy

CDC on Menopause medical therapy

Menopause medical therapy in the news

Blogs on Menopause medical therapy

Directions to Hospitals Treating Menopause

Risk calculators and risk factors for Menopause medical therapy


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Rahmah Al-Edresi, M.D.[2]

Overview

While perimenopause is a natural stage of life when the symptoms are severe, this may be alleviated through medical treatments that include Hormone therapy(HT), non-hormonal therapy, and complementary or alternative therapies.Hormonal therapy (HT) provides the best relief, but hormone therapy should only be used for the shortest duration of time and at its lowest effective dose, as it increases the relative risk of uterine cancer ,ovarian cancer, breast cancer, thromboembolism, and coronary heart disease, especially in women who start HT after menopause. Some other drugs afford limited relief from hot flashes. A woman and her doctor should carefully review her symptoms and relative risk before determining whether the benefits of HT or other therapies outweigh the risks.

Medical therapy

Hormonal replacement therapy(HRT)

Selective Estrogen Receptor Modulators (SERMs)

Other forms of hormone therapy:

Adverse effects:


Non Hormonal therapy:

Non hormonal therapy includes serotonin-norepinephrine reuptake inhibitors(SNRIs), selective serotonin reuptake inhibitors (SSRIs), clonidine, and gabapentin.

Complementary and alternative therapies:

Other therapies:

  • Individual counseling or support groups may be helpful to handle sad, depressed, or confusing feelings women may be having as their bodies change.
  • Vaginal moisturizers such as Vagisil or Replens and lubricants, such as K-Y Jelly or Astroglide can help women with thinning vaginal tissue, dryness, and decrease the pain that may be present during intercourse.
  • Moisturizers and lubricants are different products for different types of issues. Some women feel dry apart from sex and they may do better with moisturizers all the time. Those who just need lubricants are fine just using the lubrication products during intercourse. Low-dose vaginal estrogen is generally a safe way to take estrogen to solve vaginal thinning and dryness problems while only minimally increasing the levels of estrogen in the blood.
  • Drinking cold liquids and removing excess clothing layers when hot flashes strike, and avoiding hot flash triggers such as spicy foods maybe relieve some symptoms for some women.



References

  1. Kaunitz AM, Manson JE (2015). "Management of Menopausal Symptoms". Obstet Gynecol. 126 (4): 859–876. doi:10.1097/AOG.0000000000001058. PMC 4594172. PMID 26348174.
  2. North American Menopause Society (2012). "The 2012 hormone therapy position statement of: The North American Menopause Society". Menopause. 19 (3): 257–71. doi:10.1097/gme.0b013e31824b970a. PMC 3443956. PMID 22367731.
  3. Maclennan AH, Broadbent JL, Lester S, Moore V (2004). "Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes". Cochrane Database Syst Rev (4): CD002978. doi:10.1002/14651858.CD002978.pub2. PMC 7004247 Check |pmc= value (help). PMID 15495039.
  4. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M; et al. (2003). "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial". JAMA. 290 (13): 1739–48. doi:10.1001/jama.290.13.1739. PMID 14519708.
  5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995). "Hormone replacement therapy and endometrial cancer risk: a meta-analysis". Obstet Gynecol. 85 (2): 304–13. doi:10.1016/0029-7844(94)00383-O. PMID 7824251.
  6. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL; et al. (2013). "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials". JAMA. 310 (13): 1353–68. doi:10.1001/jama.2013.278040. PMC 3963523. PMID 24084921. Review in: Evid Based Med. 2014 Jun;19(3):105
  7. Bansal R, Aggarwal N (2019). "Menopausal Hot Flashes: A Concise Review". J Midlife Health. 10 (1): 6–13. doi:10.4103/jmh.JMH_7_19. PMC 6459071. PMID 31001050.


Template:WikiDoc Sources